Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer

嵌合抗原受体 癌症研究 细胞疗法 医学 T细胞 免疫疗法 表皮生长因子受体 抗原 癌症 免疫学 干细胞 生物 内科学 免疫系统 细胞生物学
作者
Hong Ma,Jeeban P. Das,Conor Prendergast,Dorine de Jong,Brian Braumuller,Jacienta Paily,Sophia Huang,Connie Liou,Anna O. Giarratana,Mahdie Hosseini,Randy Yeh,Kathleen M. Capaccione
出处
期刊:Current Issues in Molecular Biology [Caister Academic Press]
卷期号:45 (11): 9019-9038 被引量:31
标识
DOI:10.3390/cimb45110566
摘要

Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MiRoRo完成签到 ,获得积分10
1秒前
冉冉完成签到,获得积分10
2秒前
2秒前
Ava应助笛九采纳,获得10
2秒前
3秒前
Criminology34应助Singularity采纳,获得10
3秒前
4秒前
4秒前
YYY完成签到,获得积分10
4秒前
qqqqqqqqqqqq完成签到,获得积分10
6秒前
科研通AI6.3应助雅山采纳,获得10
6秒前
潇洒的惋清应助DUN采纳,获得10
7秒前
迷路的灵波应助smile采纳,获得10
7秒前
等等发布了新的文献求助10
8秒前
8秒前
小满发布了新的文献求助10
9秒前
小二郎应助ZZZ采纳,获得10
10秒前
10秒前
11秒前
英俊的铭应助研友_Ljb0qL采纳,获得10
12秒前
子任完成签到 ,获得积分10
12秒前
12秒前
muzi发布了新的文献求助10
13秒前
14秒前
wanglixiang发布了新的文献求助10
15秒前
自信的怀蝶完成签到,获得积分20
15秒前
16秒前
等等完成签到,获得积分10
17秒前
桐桐应助LegendThree采纳,获得10
17秒前
阿鹿462发布了新的文献求助10
17秒前
nanli0330发布了新的文献求助10
17秒前
青梅煮酒发布了新的文献求助10
18秒前
18秒前
笛九发布了新的文献求助10
19秒前
HUO完成签到,获得积分20
20秒前
21秒前
Xu完成签到 ,获得积分10
21秒前
21秒前
桐桐应助老六采纳,获得10
22秒前
22秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
Molecular Mechanisms of Photosynthesis, 4th Edition 1000
Organic Reactions, Volume 116 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7261955
求助须知:如何正确求助?哪些是违规求助? 8883400
关于积分的说明 18773437
捐赠科研通 6941217
什么是DOI,文献DOI怎么找? 3202346
关于科研通互助平台的介绍 2375640
邀请新用户注册赠送积分活动 2178068